The purpose of this study is to id transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular targeted therapies in patients with hepatocellular carcinoma (HCC) .
Study Type
OBSERVATIONAL
Enrollment
300
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China
RECRUITINGOverall Survival(OS)
The OS is defined as the time from the initiation of any combination treatment to death due to any cause.
Time frame: up to approximately 2 years
Specificity
The specificity of the radiomics artificial intelligence model for identifying optimal candidates among patients who treated TACE in combination with PD-1/PD-L1 inhibitors and molecular target therapy will be calculated.
Time frame: baseline
Sensitivity
The sensitivity of the radiomics artificial intelligence model for identifying optimal candidates among patients who treated TACE in combination with PD-1/PD-L1 inhibitors and molecular target therapy will be calculated.
Time frame: baseline
The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiomics artificial intelligence mode
The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiomics artificial intelligence model for identifying optimal candidates among patients who treated TACE in combination with PD-1/PD-L1 inhibitors and molecular target therapy will be calculated.
Time frame: baseline
Accuracy
Defined by a confusion matrix of sensitivity and specificity to true positives and true negatives.
Time frame: baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.